The treatment of mycosis fungoides.
Primary cutaneous T-cell lymphomas (PCLs) mycosis fungoides (MF) and Sézary syndrome (Ss) belong to the group of non-Hodgkin lymphomas (NHL), which are characterized by clonally proliferating CD4+ cells localized in the skin. Although there already exist many conventional skin-directed and systemic cytotoxic treatment options, in long-term only a transient remission without curative results will be reached in most cases. The aim of this article was to present actual assumed treatment modalities, as well as new therapeutic strategies which passed already through clinical trials showing promising results in the treatment of PCLs.
Mestel
D Sebastian
DS
Department of Dermatology and Allergy, Skin Cancer Center, Charité-Universitaetsmedizin, Berlin, Germany.
Beyer
M
M
Steinhoff
M
M
Sterry
W
W
Assaf
C
C
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D009182:Mycosis Fungoides / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D009367:Neoplasm Staging; D011701:PUVA Therapy / Q000379:methods; D017893:Photopheresis; D017410:Practice Guidelines as Topic; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D016896:Treatment Outcome; D014467:Ultraviolet Therapy
D000970:Antineoplastic Agents